Patients receiving an SGLT2 inhibitor had lower healthcare resource utilization and costs compared to those receiving a DPP4 inhibitor.
SGLT2 inhibitor patients experienced significantly fewer hospitalizations and outpatient visits per person per month.
Lengths of hospital stays were shorter for patients on SGLT2 inhibitors compared to those on DPP4 inhibitors.
Overall healthcare costs per person per month were generally lower for SGLT2 inhibitor patients.
Similar trends in healthcare resource utilization and costs were noted in patients with a higher body mass index, but not in those with a lower body mass index.
Simplified
AIMS/INTRODUCTION: Healthcare resource utilization () and healthcare costs are important factors to consider when selecting appropriate treatment for type 2 diabetes mellitus. We compared the HCRU and healthcare costs of sodium-glucose cotransporter 2 inhibitors () vs dipeptidyl peptidase-4 inhibitors () in patients with type 2 diabetes mellitus in Japan.
MATERIALS AND METHODS: This was a Japanese retrospective cohort study conducted using the JMDC Claims Database (January 1, 2015-December 31, 2021). Patients newly treated with an SGLT2i (31,872 patients) or a DPP4i (73,279 patients) were matched 1:1, using propensity score, after excluding patients without continuous SGLT2i or DPP4i prescriptions after the index date. HCRU and healthcare costs were compared between the treatment groups in the full cohort and subcohorts/subgroups of different baseline characteristics, including body mass index (BMI).
RESULTS: After matching, patient characteristics were well balanced (17,767 patients each). Patients receiving an SGLT2i vs those receiving a DPP4i had significantly lower numbers of hospitalizations per person per month (PPPM) and outpatient visits PPPM, and had shorter lengths of stay per hospitalization. Healthcare costs, including all-cause overall healthcare costs PPPM and all-cause hospitalization costs PPPM, were generally lower in patients receiving an SGLT2i than those receiving a DPP4i. Similar results were observed among patients with a higher BMI but not among patients with a lower BMI.
CONCLUSIONS: SGLT2i were associated with lower HCRU and healthcare costs than DPP4i, suggesting economic benefits with SGLT2i vs DPP4i in type 2 diabetes mellitus management.
Key numbers
0.0179
Lower Hospitalizations
Mean number of hospitalizations per person per month for
$364.2
Lower Overall Healthcare Costs
Mean all-cause overall healthcare costs per person per month for
$420.3
Higher Overall Healthcare Costs for
Mean all-cause overall healthcare costs per person per month for
Full Text
We can’t show the full text here under this license.
